2025-11796RuleWallet

FDA Classifies Newborn Muscular Dystrophy Screening Test as Device

Published Date: 6/26/2025

Rule

Summary

The FDA is officially classifying the muscular dystrophy newborn screening test as a Class II device with special controls to ensure it’s safe and effective. This change helps babies get quicker access to this important test by easing some regulatory hurdles. The new classification is effective June 26, 2025, but has been in effect since December 12, 2019, making life easier for test makers and families alike.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 1 costs, 0 mixed.

Newborn Muscular Dystrophy Test Classified Class II

The FDA classified the muscular dystrophy newborn screening test as Class II (special controls). The device is defined as an in vitro diagnostic to measure creatine kinase from dried blood spot specimens from newborns. The order is effective June 26, 2025, and the classification was applicable on December 12, 2019.

Easier Pathway for Device Makers (510(k) Predicate)

By classifying this device into Class II via the De Novo process, the FDA allows the device to serve as a predicate so future devices of that type can be cleared through the less burdensome 510(k) process instead of De Novo or premarket approval. FDA received the De Novo request on November 4, 2019, and issued the classification order on December 12, 2019.

Mandatory Clinical Validation Study Requirements

Manufacturers must perform design verification and validation that include a clinical validation study demonstrating that the analyte identifies newborns needing follow-up, shows predictive value using well-characterized specimens, uses testing by representative users, assesses sample collection effects, and provides confirmed positive specimens with diagnostic outcome information. Data must demonstrate upper reference intervals including sufficient samples to calculate the 97.5th and 99.5th percentiles.

Labeling Must Show Warnings and Test Performance

Labeling must include warnings that results are not intended to diagnose muscular dystrophies and that results should be used with other clinical findings and confirmatory methods. Labels must provide detailed device performance information, including the false positive and false negative screen rates observed in the clinical study, any study limitations, and performance in relevant subgroups (for example, age at collection, birth weight, sex, gestational age).

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
6/26/2025
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register